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Trans-splicingSigniﬁcant advances have beenmade in our understanding of heat shock protein 90 (Hsp90) in terms of its struc-
ture, biochemical characteristics, post-translational modiﬁcations, interactomes, regulation and functions. In
addition to yeast as a model several new systems have now been examined including ﬂies, worms, plants as
well as mammalian cells. This review discusses themes emerging out of studies reported on Hsp90 from infec-
tious disease causing protozoa. A common theme of sensing and responding to host cell microenvironment
emerges out of analysis of Hsp90 in Malaria, Trypanosmiasis as well as Leishmaniasis. In addition to their func-
tional roles, the potential of Hsp90 from these infectious disease causing organisms to serve as drug targets
and the current status of this drug development endeavor are discussed. Finally, a unique and the only known
example of a split Hsp90 gene from another disease causing protozoan Giardia lamblia and its evolutionary
signiﬁcance are discussed. Clearly studies on Hsp90 from protozoan parasites promise to reveal important
new paradigms in Hsp90 biology while exploring its potential as an anti-infective drug target. This article is
part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Studies on infectious disease causing organisms have uncovered
many intriguing themes in biology. Research on heat shock protein 90
(Hsp90) biology is no exception. Here too studies on infectious disease
causing microbes of protozoan origin have revealed fascinating new
insights into the functioning of this fascinating molecular chaperone.
Hsp90 is an evolutionarily conservedmolecular chaperone, essential
in all eukaryotes studied [1]. Since its original identiﬁcation as a part of
the steroid hormone receptor complex, the roles ascribed to heat shock
protein 90 have grown [2]. Today Hsp90 is believed to function not only
as a chaperone that helps proteins to fold but also more complex roles
in maintaining regulatory proteins in metastable conformations that
are poised for activation in response to speciﬁc environmental stimuli
[3,4]. These ﬁndings are now well supported by structural and mecha-
nistic data [5,6].
Hsp90 research has witnessed a very exciting phase in the last two
decades. Studies on Hsp90 biology by researchers all over the world,
have resulted in advances in three main directions. These are 1)
biochemical and structural features of Hsp90 [7–9] 2) exploration of
its role in regulating signaling events in eukaryotes [10,11] and 3) the
potential of Hsp90 to affect genetic variation and thereby evolution
[12–14]. These studies have resulted in our in-depth understanding in
these areas by relying on models such as yeast and mammalian cell
lines. These studies have also culminated in implication of Hsp90 ashock Protein 90 (HSP90).
atu@gmail.com (U. Tatu).
rights reserved.an anti-cancer target and triggered development of several naturally
occurring and synthetic inhibitors of Hsp90 by academia and industry
[15,16].
We have comprehensively summarized the knowledge gained so far
on the importance of Hsp90 in pathogenic and some non-pathogenic
protozoan species. While identifying gaps in our knowledge about
Hsp90 biology, we have attempted to emphasize themes emerging
out of research on Hsp90 in protozoan disease causing organisms and
its potential new applications in management of infectious diseases.
1.1. Hsp90 orchestrates stage transitions in protozoa
The ability of Hsp90 to sense and respond to environmental stimuli
has been cleverly exploited by protozoan parasites. As a part of their
complex life cycles protozoan parasites often alternate between two
different hosts e.g. an insect vector and a mammalian host and encoun-
ter several environmental insults which they need to acclimatize
against, in order to establish a productive infection. These differences
include temperature, pH as well as the challenge of the host immune
system. It is no surprise that these parasites critically depend on
Hsp90 to adapt and proliferate.
Malarial parasite Plasmodium falciparum provides an excellent
example of clever utilization of the Hsp90 machinery in sensing and
responding to environmental changes in the human host. The parasite
is known to experience elevated temperature shock during transmis-
sion from the insect vector to the human host. Even more importantly,
the parasite has evolved to cope with repeated temperature ﬂuctua-
tions in the form of periodic fever in the patient. These reversible and
regularly timed temperature changes are usually from 37 °C to about
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Indeed PfHsp90 is known to get induced during such temperature
changes and block of its function using speciﬁc inhibitors is known to
abrogate the parasite growth in human erythrocytes [17].
Interestingly, there is an independent observation linking the
growth of malarial parasite in the human erythrocytes with environ-
mental temperature. It is long known that transition of the malarial
parasites from early ring stage to metabolically active trophozoites
can be regulated by temperature manipulations [18]. Once again this
temperature induced stage shift can be effectively abrogated by inhibi-
tion ofHsp90. Together, these observations suggest a close link between
PfHsp90 function and growth ofmalaria parasite in human erythrocytes
[19]. As detailed below, these ﬁndings have now been exploited to
design novel, Hsp90-directed treatment of malaria.
An even more exciting example implicating the importance of
Hsp90 function in infectious diseases is provided by another related
protozoan parasite Leishmania donovani, the cause of leishmaniasis in
humans. The transformation of the leishmanial parasite from its motile,
promastigote stage in the insect vector to a non-motile, amastigote
form in the human host is known to depend on its Hsp90. The temper-
ature rise encountered by the parasite during its transmission disturbs
the Hsp90 homeostasis and results in the differentiation of promasti-
gotes to the amastigote forms. Importantly, this stage transformation
can be induced in culture by using inhibitors of Hsp90 suggesting a di-
rect link between Hsp90 function and parasite stage transition [20,21].
Studies done by Spaeth group have also shed light on the importance
of post-translational modiﬁcations of heat shock proteins and chaper-
one complexes such as STI1/Hop, as being a major factor in sensing
environmental stresses and inducing parasite differentiation [22,23].
A similar role for Hsp90 in sensing environmental cues has been
proposed in other protozoan parasites such as Eimeria [24], Theileria
[25], Toxoplasma [26], Trypanosoma [27,28] as well as in a non-
pathogenic protozoan Dictyostelium discoideum [29]. An infectious
disease causing yeast, namely Candida albicans provides yet another
example of exploitation of Hsp90 in disease pathogenesis [30,31].
1.2. A stitch in time saves 90: A trans-spliced Hsp90 from Giardia lamblia
Giardia lamblia is an early branching protozoan that has attracted a
lot of attention due to its unique position on the evolutionary ladder.
Previously believed to be a primitive eukaryote, G. lamblia is now
considered aminimalist that has all the hall marks of a complex eukary-
ote. Besides its evolutionary signiﬁcance Giardia is known to be one of
the leading causes of diarrhea in the world and there is a lot of interest
in ﬁnding better treatment strategies against this parasite that infects
humans as well as animals.
While the genome of G. lamblia was fully sequenced in 2007, the
unique organization of its Hsp90 coding gene was only recently noticed
[32]. GlHsp90 is the only example in biology so far, in which Hsp90 is
coded by two different genes that are spliced together in trans. The
genes are annotated as HspN and HspC as they code for the N- and
C-terminal halves of Hsp90 respectively. These genes are placed
777 kbp apart on the chromosome with hundreds of other protein
coding genes present in between.
Two independent groups have now shown a novel mRNA trans-
splicing event to be responsible for the production of a full length, con-
tiguous GlHsp90 mRNA [32,33]. In addition to the conventional GT/AG
splice boundary this mRNA repair is guided by a pair of complementary
RNA sequences positioned downstream of HspN and upstream of HspC
mRNA sequence (Fig. 1).While the precisemechanisms andmachinery
involved in this unique trans-splicing event need to be worked out, it is
tempting to speculate why this early branching eukaryote developed
such a circuitous route to generate one of themost abundant and essen-
tial proteins in the cell [32,33].
While a ‘genetic accident’ may have sparked off the split nature of
the Hsp90 gene in G. lamblia, its selection and genetic stabilizationprobably occurred to counter naturally occurring inhibitors of Hsp90
such as GA and radicicol. It is possible that during its millions of years
of evolution, G. lamblia encountered organisms capable of producing
such inhibitors and one way to survive this strategic attack was to pro-
duceHsp90 fragment thatwould sequester these inhibitors and thereby
allow the full length counterpart to function. Preliminary evidence from
this lab indeed suggests an independent expression of the N-terminus
of GlHsp90 both at transcript aswell as the protein level (unpublished).
Clearly protozoan parasites provide an excellent theme for Hsp90
research. These parasites are inhabitants of diverse ecological niches,
and adaptation to their unique host microenvironments critically
depends on the versatility of Hsp90 to sense and respond to cues
from the environment.
1.3. Hsp90 as an anti-infective drug target
Inhibitors of Hsp90 have not only provided an excellent tool to
dissect its function in biology but also triggered interest in their devel-
opment as drugs for disease treatment. Research on Hsp90 in models
such as yeast and mammalian cells by a large number of laboratories
has resulted in its implication as an anti-cancer drug target [15,16].
Large numbers of naturally occurring as well as synthetic inhibitors of
Hsp90 have been developed by academia and industry. Many of these
have advanced to phase II and III clinical trials [34].
Indeed there is a vast amount of information available on the struc-
tures, medicinal chemistry, toxicology as well as formulations of differ-
ent drugs that have been tried at different levels for cancer therapy. We
are presented with an opportunity to garner this knowledge available
with academia and industry and apply it for the development of anti-
infectives. Malaria by itself is responsible for about two million deaths
every year. Together with Leishmaniasis and Trypanosomiasis this
protozoan disease trio poses a major health challenge for humans and
animals in developing nations. Even with a small chance of success, it
is important to harness information available on Hsp90 directed anti-
cancer drug development programs and reposition for the development
of novel anti-malarial, anti-trypanosomal and anti-leishmanial drugs.
Some activity is already evident in this direction and at least two inde-
pendent laboratories have now reported promising outcomes in their
pre-clinical drug trials for malaria and trypanosomiasis using existing
Hsp90 inhibitors [35,36].
Often an argument is presented that inhibitors like GA and its deriv-
atives will lack speciﬁcity and will inhibit the human counterpart caus-
ing undesirable side effects in patients.While it is desirable to screen for
inhibitors speciﬁc to parasite Hsp90s, it may be important to emphasize
that S. hygroscopicus synthesizes this Hsp90 inhibitor to counter micro-
bial competition in its ecological niche. In other words, nature has
designed inhibitors such as radicicol and GA to inhibit microbial
Hsp90s. Further, judging from the use of their derivatives in
pre-clinical animal models of malaria and trypanosome it appears that
the dose regimen required for the treatment of infectionsmay be rather
short in comparison to a standard cancer chemotherapy schedule and
may be well tolerated by the patient. Given that there is a rapid emer-
gence of drug resistance reported in many protozoan and fungal infec-
tions including malaria [37], trypanosomiasis [38] and candidiasis
[39], it is important to highlight the potential of Hsp90 inhibitors to
overcome drug resistance as reported in case of C. albicans infections
[40]. In fact, given the importance of Hsp90 amongst a wide range of
protozoans, it is not premature to imagine the use of an Hsp90 inhibitor
as a broad spectrum drug against protozoan diseases (Fig. 2).
2. Conclusions
Despite overall domain conservation there are someunique features
in the primary structures of Hsp90 from protozoa that demand atten-
tion. While several differences from mammalian or the well-studied
yeast Hsp90 sequences have been reported in the ATP and drug binding
Fig. 1. Trans-spliced Hsp90 in Giardia: A. Representation of HspN and HspC ORFs on the same contig of genomic DNA. mRNA of Hsp90 (cDNA) is found to be a fused product of HspN
and HspC transcripts, a resultant of splicing in trans. B. The positioning elements (red boxes), nearly complementary sequences, from HspN and HspC bring the pre-mRNAs together
spatially. Base pairing between the positioning elements brings the cleavage sites (asterisks) into proximity. The respective sequences of positioning elements are shown below.
Dotted lines indicate ORF boundaries that are excised during the splicing reaction. Figure adopted from Nageshan et al. [32].
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strikingly clusters among a groupof protozoa [35]. The precise inﬂuence
of this change on its afﬁnity for ATP or GA has not been examinedFig. 2. Protozoan Hsp90 from bench to bedside: the biological aspects of Hsp90 have been repr
Hsp90 in regulating critical pathways in protozoa such as P. falciparum (33), T. gondii (24), E.
L. donovani (20, 21). The outermost (yellow) circle signiﬁes the use of Hsp90 inhibitor as a brosystematically. Another important difference lies in the linker region
between the amino terminal nucleotide binding domain and middle
domain. Hsp90 from protozoa often have extended linkers with P.esented in the concentric circles. The pink and lavender circles highlight the importance of
tenella (22), T. parva (23, 39, 40), G. lamblia (32), D. discoideum (27), T. evansi (33) and
ad spectrum anti-protozoan agent.
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Conformational ﬂexibility conferred by the linker region is gaining
signiﬁcant attention not only in regulating the conformational dynam-
ics but also in inﬂuencing their afﬁnities for drugs such asGA. A compar-
ative analysis of PfHsp90 with its human counterpart as well as linker
swapping experiments will be very useful in understanding the role of
the linker in Hsp90 biology.
Hsp90 from protozoan infection causing parasites differ from their
human counterpart in their biochemical characteristics also. Differences
in their abilities to catalyzeATP hydrolysis is particularly striking. Hsp90
from P. falciparum exhibits about 6 times higher ATPase activity as com-
pared to its human counterpart. Differences have also been reported in
the sites of post-translational modiﬁcations of Hsp90 from humans. In
addition to inﬂuencing Hsp90 reaction cycles these differences may
impact their sensitivities to Hsp90 inhibitors and may provide the
bases for designing speciﬁc drugs [35].
Protozoa also present a convenient model to understand the roles
of Hsp90 co-chaperones. A quick look at the genome data of many of
these organisms reveals that the Hsp90 co-chaperone repertoire in
these organisms is often incomplete. CDC37, p23, Aha1 or cyclophilin
homologs are missing in many of the protozoa [41]. It will be interest-
ing to understand the impact of omission of these co-chaperones on
the Hsp90 chaperone cycles in these parasites.
Research onHsp90 in protozoan infectious diseases is still at an early
stage. While several laboratories have emphasized the critical roles
played by Hsp90 in the complex life cycles of protozoa such as Giardia,
Leishmania, Theileria, Plasmodium, Eimeria, Toxoplasma, aswell as Trypa-
nosoma, speciﬁc mechanisms remain to be elucidated. Much of the
available information about downstream pathways is at best descrip-
tive. Unlike models such as yeast and mammalian cells, we do not
have speciﬁc information on client proteins regulated by Hsp90 in
protozoan infectious agents. While orthologs of some of the known
clients have been found, many others appear divergent and remain to
be identiﬁed. For example the canonical heat shock factor in P. falci-
parum is prominently missing.
Finally, the only example of a split Hsp90 gene that depends on a
novel trans-splicing event for its expression reported in G. lamblia,
provides an unprecedented glimpse into the epic effort made by this
early branching eukaryote to maintain the ‘split nature’ of this essential
gene. The trans-spliced nature of Hsp90 in G. lamblia provides a whole
new perspective to address questions related to its structure, regulation
as well as aspects of its evolution.
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